A significant development in the fight against infectious diseases has emerged from Georgia State University, where researchers have formulated an experimental oral antiviral compound demonstrating remarkable efficacy in preventing the spread of a measles-like virus. This novel drug, designated GHP-88310, successfully interrupted transmission between test subjects through both direct physical interaction and aerosolized particles, while also mitigating disease severity when administered either preemptively or shortly after exposure. The findings, recently detailed in the journal Nature Microbiology, offer a potentially transformative tool in public health arsenals, particularly as regions globally grapple with the re-emergence of highly contagious pathogens like measles.
The research, spearheaded by scientists at Georgia State’s Center for Translational Antiviral Research (CTAR), focused on canine distemper virus (CDV). CDV was selected due to its capacity to induce a clinical syndrome in ferrets that closely mirrors the symptoms and pathological progression of human measles infection, making it an ideal surrogate model for studying measles transmission and therapeutic interventions. This strategic choice allowed the team to rigorously evaluate the drug candidate’s potential in a controlled, biologically relevant system.
GHP-88310 operates as a broad-spectrum inhibitor targeting the viral polymerase enzyme. This enzyme is absolutely critical for the replication cycle of many RNA viruses, including measles and canine distemper. By interfering with the polymerase, GHP-88310 effectively halts the virus’s ability to create new genetic material and, consequently, to produce new viral particles, thereby stifling the infection at its source. The oral administration route is a crucial practical advantage, simplifying deployment during outbreaks and potentially improving patient compliance compared to injectable treatments.
One of the study’s most compelling outcomes was GHP-88310’s ability to block two primary modes of viral transmission. Measles is notoriously contagious, known for its rapid spread through both respiratory droplets (airborne transmission) and direct contact with infected individuals or contaminated surfaces. The experimental design meticulously replicated these real-world scenarios, establishing a controlled environment where infected and uninfected ferrets either shared close physical proximity or occupied the same airspace without direct physical contact. In both experimental setups, the administration of GHP-88310 as a prophylactic measure — meaning given either just before or immediately after potential exposure — completely prevented the transmission of the measles-like virus. This dual-route blockage represents a significant advancement, particularly the interruption of airborne spread, which is a hallmark of highly transmissible respiratory viruses.
Beyond its prophylactic capabilities, the research also highlighted the therapeutic potential of GHP-88310. For animals that were already infected, the drug demonstrated an ability to reduce the duration of illness and, crucially, to shorten the period during which they remained capable of transmitting the virus to others. This dual functionality – preventing infection and reducing the infectious window – positions GHP-88310 as a versatile agent for managing and containing outbreaks. Senior author Richard Plemper, a Regents’ Professor and director of the CTAR, underscored the urgency of these findings. "The swift containment of measles outbreaks is paramount to re-establishing control over this highly virulent pathogen," Plemper stated. "This investigation builds upon our prior work on GHP-88310, providing compelling evidence that this drug is suitable to enhance conventional ring vaccination strategies against measles."
The implications of these findings are particularly pertinent given the global resurgence of measles. Once considered largely eradicated in many developed nations thanks to widespread vaccination programs, measles has experienced a troubling comeback in recent years. In North America, specifically, the United States has seen a concerning rise in cases since 2025, leading to thousands of documented infections across multiple states, hundreds of hospitalizations, and at least three confirmed fatalities. Similar significant outbreaks, including those with multiple deaths, have also been reported in Canada and Mexico. This re-emergence poses a substantial threat to the hard-won "elimination status" previously achieved for measles in these regions, signaling a critical public health challenge that demands innovative solutions beyond existing strategies. The highly contagious nature of measles, characterized by an R0 (basic reproduction number) that can exceed 12-18, means that a single infected individual can quickly transmit the virus to many others in an unvaccinated or under-vaccinated community, leading to rapid exponential growth of cases.
Carolin Lieber, the study’s first author and a senior postdoctoral fellow in the Plemper laboratory, expressed enthusiasm regarding the drug’s potent effects. "We were incredibly encouraged to observe that orally administered GHP-88310 completely averted airborne transmission within our ferret model of measles," Lieber remarked. "Such an outcome is unprecedented for a viral polymerase inhibitor and powerfully illustrates the extraordinary antiviral strength of this compound." This emphasizes the novelty and potential impact of GHP-88310, as preventing airborne transmission is one of the most challenging aspects of controlling respiratory viral spread.
The meticulous design of the study aimed to create conditions that mirrored real-world human interactions and transmission risks. Researchers deliberately constructed experimental setups to simulate viral propagation within close-contact environments, akin to interactions occurring within a household, as well as scenarios involving more distant social connections, such as those found in classrooms or other indoor public settings where individuals are in proximity but may not have direct physical contact. This methodological rigor enhances the translational relevance of the findings, suggesting that GHP-88310 could be effective in diverse human outbreak settings. Plemper further elaborated on the broader societal benefits: "Beyond its preventative capacity, the therapeutic application of GHP-88310 significantly reduced the duration of disease in our model. If these benefits extend to human patients, it could substantially alleviate the severe social and economic burdens associated with prolonged patient quarantines, further bolstering outbreak management efforts." The financial strain of extended quarantines, including lost wages, healthcare costs, and disruption to education and business, represents a significant societal cost that an effective antiviral could help mitigate.
The successful preclinical results have paved the way for the next critical phase of development. The research team is now actively preparing GHP-88310 for formal clinical trials, a rigorous process required to assess its safety, dosage, and efficacy in human subjects. This move signifies a crucial step toward potentially bringing this promising antiviral from the laboratory to patient care, offering a new line of defense against measles and other related viral threats.
The groundbreaking research was supported by critical funding from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), underscoring the importance of government investment in infectious disease research. Additional significant contributions to the study were provided by Josef Wolf, Claire Ruckel, and Lauren Harrison, all affiliated with the Center for Translational Antiviral Research within the Institute for Biomedical Sciences at Georgia State University. Their collective efforts highlight the collaborative nature of scientific discovery in addressing pressing global health challenges.
About the Author
